Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus SOX perioperative therapy for resectable locally advanced gastric adenocarcinoma
ChiCTR2100043572Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, oxaliplatin and tegafur in gastric adenocarcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: 2-year disease-free survival rate. Started Dec 2020; status: recruiting.
02
Drugs
sintilimaboxaliplatintegafur
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100043572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043572.